產(chǎn)品詳情
簡單介紹：
重組人干擾素-β1b蛋白與其它公司提供的重組蛋白不同，rHuIFN-β1b蛋白產(chǎn)品為采用CFS的無細胞麥胚蛋白合成系統(tǒng)表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人干擾素-β1b蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人干擾素-β1b蛋白
| Species | Human |
| Accession | P01574 |
| GeneID | 3456 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人干擾素-β1b蛋白Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids. |
| Quantity | 2μg/10μg/1000μg |
| AA Sequence | MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人干擾素-β1b蛋白Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 3.0 × 107 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4, containing 2 % HSA and 3 % mannitol. |
| Endotoxin | Less than 1 EU/μg of rHuIFN-β1b as determined by LAL method. |
| Reconstitution | 重組人干擾素-β1b蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人干擾素-β1b蛋白 | |
| Reference |
1. Yoshino A, Tashiro S, Ogino A, et al. 2011. Int J Oncol, 39: 529-42. 2. Farrell RA, Marta M, Gaeguta AJ, et al. 2012. Rheumatology (Oxford), 51: 590-9. 3. Breckpot K, Corthals J, Bonehill A, et al. 2005. J Leukoc Biol, 78: 898-908. 4. Oger J, Francis G, Chang P. 2005. J Neurol Sci, 237: 45-52. 5. Giorelli M, Livrea P, Trojano M. 2005. J Interferon Cytokine Res, 25: 395-406. |
| Background | IFN-βs are proteins produced by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They have antiviral activity that it is mainly involved in innate immune response. The IFN-β family has 2 subtypes，which are IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. |
